Blueprint Medicines Corporation
Clinical trials sponsored by Blueprint Medicines Corporation, explained in plain language.
A precision medicine company developing targeted therapies for cancer and rare diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill could tame stubborn hives that antihistamines Can't stop Results expected Dec 2026 (estimated)
- New drug aims to ease symptoms of rare mast cell disease Results expected Jun 2027 (estimated)
-
New targeted pill shows promise for rare blood cancer
Disease control CompletedThis Phase 2 study tested avapritinib, a daily tablet that targets a specific genetic mutation, in 107 people with advanced systemic mastocytosis (a rare blood cancer). The main goal was to see how many patients had their tumors shrink or symptoms improve. Results suggest the dru…
Phase 2 • Sponsor: Blueprint Medicines Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hope for kids with rare cancers: targeted drug shows promise
Disease control CompletedThis study tested a drug called avapritinib in 29 children aged 2 to 18 with advanced solid tumors that have specific genetic changes (KIT or PDGFRA). The goal was to see if the drug is safe and can shrink or control the tumors. Participants took the drug by mouth, and researcher…
Phase 1/2 • Sponsor: Blueprint Medicines Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New allergy pill shows promise in ragweed season trial
Symptom relief CompletedThis study tested a new drug called BLU-808 in 21 adults with ragweed allergies. The goal was to see if it is safe and helps reduce sneezing, runny nose, and itchy eyes caused by ragweed pollen. Participants were exposed to ragweed in a special chamber to measure the drug's effec…
Phase 2 • Sponsor: Blueprint Medicines Corporation • Aim: Symptom relief
Last updated Sep 05, 2026 00:00 UTC
-
New cancer Drug's interactions under the microscope
Knowledge-focused CompletedThis completed Phase 1 study looked at how a new drug called elenestinib affects the way the body processes midazolam (a sedative) and a common birth control pill. Twenty healthy adult women took these drugs with and without elenestinib, and researchers measured drug levels in th…
Phase 1 • Sponsor: Blueprint Medicines Corporation • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:10 UTC